Tiny Gem Archives - Page 3 of 66

WednesdayMay 13, 2026 10:00 am

Pentagon Seeks to Mitigate Quantum Computing Risks to the F-35

The Pentagon is taking steps toshield the F-35's encryption systems from the growing threat posed by quantum computing. A contract notice published May 6, 2026, by the F-35 Joint Program Office signals the shift to quantum computing-proof encryption. The military is moving to future-proof one of the jet's core security systems before quantum computing advances enough to break current encryption. Known as the In-Line File Encryption Device, the component at the center of this work is a specialized security chip embedded in the aircraft. Its job is to check that every piece of software on the jet is genuine and…

MondayMay 11, 2026 9:05 am

Study Suggests Timing of Immunotherapy Could Impact Clinical Outcomes

A systematic review in JAMA Network Open suggests earlier administration of immune checkpoint inhibitor therapies may improve survival outcomes in patients being treated for late-stage solid tumors. The analysis pooled data from 29 studies encompassing more than 6,000 patients. Earlier timing was linked to gains in both survival endpoints, though prospective validation is required before scheduling adjustments can be broadly adopted. The studies covered tumor types like melanoma, gastric, renal cell, esophageal, small cell lung, urothelial, biliary tract, and hepatocellular carcinoma. Twenty-seven of the 29 were retrospective cohorts. The other two comprised a randomized trial in non-small cell lung cancer and a prospective cohort study in head and neck squamous cell carcinoma. The breadth of coverage reflects growing interest in whether treatment timing, not…

ThursdayMay 07, 2026 9:00 am

Frontieras North America’s Transformative Technology Reimagines Coal for the Future

Coal remains the largest source of electricity generation in the world. At the heart of Frontieras’s FASForm technology is a continuous solid carbon fractionation process that thermally cracks coal in a reducing atmosphere. Beyond fuels and hydrogen, the FASForm process enables the creation of additional valuable industrial chemicals and materials. Global energy systems are under increasing strain as industrial demand accelerates and reliable baseload power becomes more critical to economic stability. Frontieras North America is developing a breakthrough energy-processing technology known as FASForm(TM) that deconstructs coal and other solid hydrocarbons into multiple high-value fuels and industrial products, redefining the utility and economics of coal…

WednesdayMay 06, 2026 10:00 am

Blocking Fructose Metabolism Boosts Immune Response to Childhood Cancer

Researchers at Johns Hopkins may have found a new approach to group 3 medulloblastoma, a deadly and hard-to-treat pediatric brain cancer. Mouse experiments suggest that disrupting how tumor cells generate energy can slow the disease. The research was conducted at the Kimmel Cancer Center and published in Acta Neuropathologica Communications. Group 3 medulloblastoma is one of the most difficult pediatric brain cancers to treat, and effective therapies remain scarce. The new research reveals how tumor cells rewire their energy production to fuel rapid growth. It also shows that interfering with those processes can slow the disease. Senior author Ranjan Perera, Ph.D., of Johns Hopkins All Children's Hospital, said the work points toward a largely unexplored therapeutic avenue. According…

MondayMay 04, 2026 10:00 am

Study Finds That Vitamin D Supercharges Chemotherapy Against Breast Cancer

A clinical trial in Brazil has found that adding a daily vitamin D supplement to standard chemotherapy improved outcomes for women with breast cancer. The finding contributes to growing interest in low-cost nutritional approaches that could enhance cancer treatment. Unlike many pharmaceutical agents designed to boost chemotherapy response, such an intervention would be widely accessible and inexpensive. The implications extend to any clinical setting seeking affordable ways to improve treatment response in breast cancer. Conducted at the oncology clinic of FMB-UNESP, São Paulo State University's medical school, the trial enrolled 80 women over the age of 45. Participants were split into equal cohorts, one…

WednesdayApr 29, 2026 10:00 am

3 Breakthroughs Showing Quantum Computing is Closer Than Initially Thought

Quantum computing has long been described as a technology perpetually a decade away from practical relevance. However, recent advancements in the technology may bring quantum computing to bear sooner than projected. Three areas of recent progress tell that story: hardware stability, real-world problem-solving, and the resource requirements for error correction. In each, results have arrived sooner than most of the research community predicted. For starters, continued research into quantum computing has made the technology more stable over time. Qubits are the computing units of quantum machines, capable of representing multiple states simultaneously rather than being limited to a binary value. That capability enables computations classical systems cannot match, but qubits are highly sensitive to interference and can…

MondayApr 27, 2026 10:00 am

New Molecule May Open New Therapeutic Pathway Against Brain Cancer

Researchers at Brown University Health have identified a molecule that could potentially alter how glioblastoma responds to treatment. Glioblastoma is the deadliest and most prevalent form of brain cancer affecting adults, with a five-year survival rate of just 5%-10%. The molecule, designated miR-181d, is a type of microRNA that appears to work through two separate biological mechanisms. Early findings suggest it could open treatment to patients currently beyond the reach of existing therapies. Brown University Health's study began with an unusual patient group: individuals who survive the disease far longer than their prognosis would predict. The team analyzed hundreds of…

WednesdayApr 22, 2026 10:00 am

Early Trial Suggests mRNA Vaccine Could Be Effective Against Pancreatic Cancer

A personalized mRNA vaccine has shown signs of meaningfully extending survival in pancreatic cancer patients. Six-year results from a small but closely tracked clinical trial support that conclusion. The findings are being presented at a major oncology conference in San Diego. For a disease that has historically resisted immune-based treatments, the data represents a notable step forward in making the disease more responsive to immunotherapy. Donna Gustafson, who in 2020 became the first person to receive such a vaccine for pancreatic cancer, is among those still alive. Pancreatic cancer is among the most difficult malignancies to detect and treat. No dependable early detection method exists.…

MondayApr 20, 2026 10:00 am

Encryption Codes at Risk as Quantum Computing Advances

Most digital communications are secured by encryption built on mathematical problems so hard that conventional computers cannot realistically solve them. That assumption could soon be broken by quantum computers that exploit properties of matter at subatomic scales to perform certain calculations far more efficiently than conventional machines ever could. Such systems may be capable of breaking widely used encryption methods considerably sooner than researchers had expected. Recent results from 2026 have raised concerns about quantum-based security issues in digital spaces. IBM has built a 120-qubit processor targeting quantum advantage on certain tasks, with a fully fault-tolerant machine on its roadmap for 2029. Google is moving to accelerate its own adoption of quantum-resistant…

FridayApr 17, 2026 10:50 am

Precision Oncology Is Shifting Toward Combination Strategies, Ultimately Changing How New Therapies Are Built

Targeted cancer therapies are increasingly being paired with immunotherapy and chemotherapy to improve outcomes across multiple tumor types First-in-class PP2A inhibitor LB-100 is designed to enhance treatment response by disrupting cancer cell repair mechanisms and boosting immune activity Ongoing clinical trials are exploring LB-100 across solid tumors, including ovarian and colorectal cancers, where unmet need remains high Cancer treatment is entering a phase where the question is no longer which single therapy works best, but how treatments can be combined to improve outcomes. Across oncology, resistance and relapse remain persistent challenges, and the industry’s response has been increasingly clear: multi-drug…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000

Category: Tiny Gem